Clinical trial
Randomized, 2-Way Crossover, Bioequivalence Study of Ramipril 10 mg Capsule and Altace® Administered as 1 x 10 mg Capsule in Healthy Subjects Under Fed Conditions
NCT00829530 is registered in ClinicalTrials.gov with Teva Pharmaceuticals USA as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Randomized, 2-Way Crossover, Bioequivalence Study of Ramipril 10 mg Capsule and Altace® Administered as 1 x 10 mg Capsule in Healthy Subjects Under Fed Conditions
- Lead sponsor
- Teva Pharmaceuticals USA
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- August 31, 2004
- Completion date
- October 31, 2004
- Enrollment
- 40 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.
healthy